

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 241)

POSITIVE PROFIT ALERT

This announcement is made by Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company announces to the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the unaudited consolidated management accounts of the Group and information currently available to the Board, the Group expects to record a net profit of not less than RMB450 million for the year ended March 31, 2023, as compared with a net loss of approximately RMB265.9 million for the year ended March 31, 2022. The Board believes such turnaround from loss to profit is mainly attributable to, among other things, (i) the operation refinement of the Group’s business and digitalization upgrades, which has improved the Group’s pricing capabilities and enhanced its operational efficiency; and (ii) the continuous improvement in the Group’s delivery of medical and health services and product experience to users, which has developed the habit of users purchasing pharmaceutical products on the Group’s platforms.

The information contained in this announcement represents a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group and other information currently available to the Board. Such information has not been reviewed by the auditors or the audit committee of the Company. As the Company is still in the process of finalizing its annual financial results for the year ended March 31, 2023 (the “**Annual Results**”), the actual results for the year ended March 31, 2023 may be different from the information set out in this announcement. Further details of the Annual Results will be included in the Company’s Annual Results announcement, which is expected to be published in late May 2023.

Shareholders and potential investors should exercise caution when they deal or contemplate dealing in the shares or other securities of the Company.

By Order of the Board
Alibaba Health Information Technology Limited
Zhu Shunyan
Chairman and Chief Executive Officer

Hong Kong, May 5, 2023

As at the date of this announcement, the Board comprises Mr. Zhu Shunyan, Mr. Shen Difan and Mr. Tu Yanwu as the executive Directors; Mr. Li Faguang as the non-executive Director; and Mr. Luo Tong, Mr. Wong King On, Samuel and Ms. Huang Yi Fei (Vanessa) as the independent non-executive Directors.